Company profile
Disc Medicine, Inc.
NASDAQ:IRONBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BITOPERTIN | phase3 | — | 3 | active |
| Selcodebart | phase2 | — | 4 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07187973 | phase1 | recruiting | 2026-01-06 | 2027-06-01 | Disc Medicine, Inc | A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) |
| NCT06985147 | phase2 | active_not_recruiting | 2025-08-12 | 2027-02-01 | Disc Medicine, Inc | A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) |
| NCT06050915 | phase1 | completed | 2023-10-03 | 2024-07-09 | Disc Medicine, Inc | A Study of DISC-3405 in Healthy Volunteers |
| NCT05883748 | phase2_3 | enrolling_by_invitation | 2023-08-31 | 2028-06-01 | Disc Medicine, Inc | HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP |
| NCT06910358 | phase3 | active_not_recruiting | 2025-04-04 | 2026-09-01 | Disc Medicine, Inc | Study of Bitopertin in Participants With EPP or XLP (APOLLO) |
FDA applications (0)
No records yet.